IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2737-2746

  Waddell, Amanda ^a   Vallance, Jefferson E ^a   Moore, Preston D ^b   Hummel, Amy T ^a   Wu, David ^a   Shanmukhappa, Shiva K ^a   Fei, Lin ^a   Washington, M Kay ^b   Minar, Phillip ^a   Coburn, Lori A ^b,c   Nakae, Susumu ^d   Wilson, Keith T ^b,c   Denson, Lee A ^a   Hogan, Simon P ^a   Rosen, Michael J ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

epithelial cells; inflammatory bowel disease; interleukin 33; oxazolone; ulcerative colitis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; INTERLEUKIN 33; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; CYTOKINE; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN RECEPTOR; OXAZOLONE;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHILD; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE EXACERBATION; DISEASE SEVERITY; EPITHELIAL BARRIER FUNCTION; GOBLET CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; INTESTINE FUNCTION; MALE; MOUSE; NONHUMAN; OXAZOLONE-INDUCED COLITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH PROTECTION; TRANSEPITHELIAL RESISTANCE; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; COLITIS; COLON; INTESTINE; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANIMALS; CHILD; COLITIS; COLITIS, ULCERATIVE; COLON; CYTOKINES; GOBLET CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; INTESTINAL MUCOSA; INTESTINES; MICE; OXAZOLONE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84948124280     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000532     Document Type: Article

References (49)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476.
2. Allison J, Herrinton LJ, Liu L, et al. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008;6:999-1003.
3. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cyto-kine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-490.
4. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827-840.
5. Pei C, Barbour M, Fairlie-Clarke KJ, et al. Emerging role of interleukin-33 in autoimmune diseases. Immunology. 2014;141:9-17.
6. Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188:3488-3495.
7. Hardman CS, Panova V, McKenzie ANJ. IL-33 citrine reporter mice reveal the temporal and spatial expression of IL-33 during allergic lung inflammation. Eur J Immunol. 2012;43:488-498.
8. Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464: 1367-1370.
9. Kurowska-Stolarska M, Stolarski B, Kewin P, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009;183:6469-6477.
10. Louten J, Rankin AL, Li Y, et al. Endogenous IL-33 enhances Th2 cyto-kine production and T-cell responses during allergic airway inflammation. Int Immunol. 2011;23:307-315.
11. Barlow JL, Bellosi A, Hardman CS, et al. Innate IL-13-producing nuo-cytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol. 2012;129:191-198.e191-194.
12. Humphreys NE, Xu D, Hepworth MR, et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180: 2443-2449.
13. Hung LY, Lewkowich IP, Dawson LA, et al. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci USA. 2013;110:282-287.
14. Bonilla WV, Frohlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science. 2012;335:984-989.
15. Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol. 2011;187:4598-4610.
16. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105: 10913-10918.
17. Beltran CJ, Nunez LE, Diaz-Jimenez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1097-1107.
18. Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999-1007.
19. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA. 2010;107:8017-8022.
20. Seidelin JB, Bjerrum JT, Coskun M, et al. IL-33 is upregulated in colo-nocytes of ulcerative colitis. Immunol Lett. 2010;128:80-85.
21. Latiano A, Palmieri O, Pastorelli L, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One. 2013;8:e62144.
22. Imaeda H, Andoh A, Aomatsu T, et al. Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. Int J Mol Med. 2011;28:573-578.
23. Grobeta P, Doser K, Falk W, et al. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis. 2012;18:1900-1909.
24. Duan L, Chen J, Zhang H, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med. 2012;18:753-761.
25. Sedhom MA, Pichery M, Murdoch JR, et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013;62:1714-1723.
26. Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188:1929-1939.
27. Rosen MJ, Chaturvedi R, Washington MK, et al. STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. J Immunol. 2013;190:1849-1858.
28. Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191:1069-1076.
29. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107:18581-18586.
30. Kennedy RJ, Hoper M, Deodhar K, et al. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br J Surg. 2000; 87:1346-1351.
31. Forbes EE, Groschwitz K, Abonia JP, et al. IL-9-and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med. 2008;205:897-913.
32. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999;116:301-309.
33. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564-568.
34. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002;17:629-638.
35. Iijima H, Neurath MF, Nagaishi T, et al. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med. 2004;199:471-482.
36. Li J, Razumilava N, Gores GJ, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014;124:3241-3251.
37. Seidelin JB, Coskun M, Kvist PH, et al. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J Gastroenterol. 2015;50:180-190.
38. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20:791-800.
39. McSorley HJ, Blair NF, Smith KA, et al. Blockade of IL-33 release and suppression of type 2 innate lymphoid cell responses by helminth secreted products in airway allergy. Mucosal Immunol. 2014;7:1068-1078.
40. Hoshino K, Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med. 1999;190:1541-1548.
41. Gonzalez-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008;1778:729-756.
42. Howe HS, Cheung PL, Kong KO, et al. Transforming growth factor beta-1 and gene polymorphisms in oriental ankylosing spondylitis. Rheumatology (Oxford). 2005;44:51-54.
43. Dai C, Zhao DH, Jiang M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int JMol Med. 2012;29:202-208.
44. Yang Z, Sun R, Grinchuk V, et al. IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent. Am J Physiol Gastrointest Liver Physiol. 2013;304:G381-G389.
45. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
46. Dharmsathaphorn K, McRoberts JA, Mandel KG, et al. A human colonic tumor cell line that maintains vectorial electrolyte transport. Am J Physiol 1984;246:G204-G208.
47. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is con-stitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PLoS One. 2008;3:e3331.
48. Bessa J, Meyer CA, de Vera Mudry MC, et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. JAutoimmun. 2014;55:33-41.
49. Sattler S, Ling GS, Xu D, et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun. 2014;50:107-122.